Major employers like HCA Healthcare are removing coverage for obesity drugs Wegovy and Zepbound due to surging costs, instead directing employees to manufacturer-sponsored cash-pay programs. While Eli Lilly and Novo Nordisk market these direct-to-consumer options as expanded access, experts warn they effectively allow companies to offload the financial burden onto workers. This shift highlights a growing tension where corporate cost-cutting strategies may render these essential peptide treatments unaffordable for the patients who need them.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.